These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 32241197

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY, Ding W, Zhang C, Fu L, Xu DX, Chen X.
    Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
    [Abstract] [Full Text] [Related]

  • 44. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S, Wu Y, Zhao Z, Wu B, Sun K, Wang H, Qin L, Bai F, Leng Y, Tang W.
    Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
    [Abstract] [Full Text] [Related]

  • 45. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J, Liu M, Li Y, Sun DD, Shu Z, Tan Q, Guo S, Xie R, Gao L, Ru H, Zang Y, Liu H, Li J, Zhou Y.
    J Med Chem; 2020 Nov 12; 63(21):12748-12772. PubMed ID: 32991173
    [Abstract] [Full Text] [Related]

  • 46. Nonsteroidal FXR Ligands: Current Status and Clinical Applications.
    Gege C, Hambruch E, Hambruch N, Kinzel O, Kremoser C.
    Handb Exp Pharmacol; 2019 Nov 12; 256():167-205. PubMed ID: 31197565
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
    Vignozzi L, Filippi S, Comeglio P, Cellai I, Sarchielli E, Morelli A, Rastrelli G, Maneschi E, Galli A, Vannelli GB, Saad F, Mannucci E, Adorini L, Maggi M.
    Mol Cell Endocrinol; 2014 Mar 25; 384(1-2):143-54. PubMed ID: 24486698
    [Abstract] [Full Text] [Related]

  • 53. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L, Morelli A, Cellai I, Filippi S, Comeglio P, Sarchielli E, Maneschi E, Vannelli GB, Adorini L, Maggi M.
    J Steroid Biochem Mol Biol; 2017 Jan 25; 165(Pt B):277-292. PubMed ID: 27425465
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.
    Rau M, Geier A.
    Expert Rev Clin Pharmacol; 2021 Mar 25; 14(3):333-340. PubMed ID: 33535836
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.